KARIHTALA, Peeter. How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?. Acta Oncologica, [S. l.], v. 64, p. 815–829, 2025. DOI: 10.2340/1651-226X.2025.43645. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/43645. Acesso em: 11 may. 2026.